NICE go-ahead for alzheimer's drugs.
The end of 'postcode prescribing' heralded by the long awaited National Institute for Clinical Excellence decision on drugs for Alzheimer's disease has been welcomed by the Alzheimer's Society. This will mean that the three drugs currently licensed in the UK and used to alleviate the symptoms of Alzheimer's disease, Aricept, Exelon and Reminyl, should be made available through the NHS across England and Wales. Research carried out at the Maudsley Hospital, London last October showed that half of health authorities failed to provide funds to enable people with Alzheimer's disease to benefit from treatment.